✦ LIBER ✦

A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1

✍ Scribed by Lawitz, Eric; Poordad, Fred; Kowdley, Kris V.; Cohen, Daniel E.; Podsadecki, Thomas; Siggelkow, Sara; Larsen, Lois; Menon, Rajeev; Koev, Gennadiy; Tripathi, Rakesh; Pilot-Matias, Tami; Bernstein, Barry

Book ID: 120662362
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 530 KB
Volume: 59
Category: Article
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2013.02.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

929e PEARL-II: Randomized Phase 3 Trial

929e PEARL-II: Randomized Phase 3 Trial of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333 With or Without Ribavirin in Hepatitis C Virus Genotype 1b-Infected, Treatment-Experienced Patients

✍ Andreone, Pietro; Colombo, Massimo; Enejosa, Jeffrey V.; Koksal, Iftihar; Ferenc 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 50 KB

O1 SAPPHIRE II: PHASE 3 PLACEBO-CONTROLL

O1 SAPPHIRE II: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333, AND RIBAVIRIN IN TREATMENT-EXPERIENCED ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1

✍ Zeuzem, S.; Jacobson, I.; Baykal, T.; Marinho, R.T.; Poordad, F.; Bourliere, M.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 152 KB

235 SAPPHIRE II: Phase 3 Placebo-Control

235 SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333, and Ribavirin in 394 Treatment-Experienced Adults With Hepatitis C Virus Genotype 1

✍ Jacobson, Ira M.; Zeuzem, Stefan; Baykal, Tolga; Marinho, Rui T.; Poordad, Fred; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 361 KB

475 SAPPHIRE I: Phase 3 Placebo-Controll

475 SAPPHIRE I: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333, and Ribavirin in 631 Treatment-Naïve Adults With Hepatitis C Virus Genotype 1

✍ Kowdley, Kris V.; Feld, Jordan J.; Coakley, Eoin; Sigal, Samuel; Nelson, David R 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 825 KB

O60 SAPPHIRE I: PHASE 3 PLACEBO-CONTROLL

O60 SAPPHIRE I: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333, AND RIBAVIRIN IN 631 TREATMENT-NAIVE ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1

✍ Feld, J.J.; Kowdley, K.V.; Coakley, E.; Sigal, S.; Nelson, D.; Crawford, D.; Wei 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Prediction of nonSVR to therapy with peg

Prediction of nonSVR to therapy with pegylated interferon-α2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment

✍ E. Lukasiewicz; M. Gorfine; L. S. Freedman; J.-M. Pawlotsky; S. W. Schalm; C. Fe 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB